[tdc_zone][vc_row][vc_column width=”1/2″][td_block_text_with_title custom_title=”Sellas Life Sciences (NASDAQ: SLS)”]
Sellas Life Sciences Group Inc (NASDAQ: SLS) is an immuno-pharmaceutical company. At the moment the company is in late stage clinical development with its flagship product, galinpepimut-S, also known as GPS.
GPS is being developed as a potential clinical option to treat various types of cancer. On June 19, 2019, the company announced that it received funding to move into a pivotal study of GPS as a result of a public offering of common stock and warrants.
Visit the Sellas Life Sciences investor relations website here.
[/td_block_text_with_title][td_block_18 custom_title=”Sellas Life Sciences (NASDAQ: SLS) Reports From Alpha Stock News” limit=”3″ tag_slug=”SLS”][/vc_column][vc_column width=”1/2″ vertical_align=”top”][vc_widget_sidebar sidebar_id=”td-sls”][/vc_column][/vc_row][vc_row row_divider_top=””][vc_column width=”1/1″][vc_widget_sidebar sidebar_id=”td-sls-bottom”][/vc_column][/vc_row][/tdc_zone]